ENTERA BIO LTD (ENTX) is drawing unusual attention today. Our newswire has captured 1 story on ENTX across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 24/100).
Entera Bio (ENTX) stock is moving sharply higher on Thursday with a 12.2% gap open and a current price of $3.85. The stock has surged to an intraday high of $4.20, driven by the announcement of a $275 million private placement that will fund the company’s Phase 3 clinical trials for EB613 and EB612. The financing, which is oversubscribed, is expected to extend the company’s cash runway through 2030.
Entera Bio has priced a $275 million private placement, a move that has triggered significant investor interest and a strong intraday response. The company disclosed that the financing will support the development of its two lead programs, EB613 and EB612, which are in Phase 3 trials. The transaction is expected to provide the necessary capital to advance these programs and extend the company’s financial runway until 2030. The announcement was accompanied by a securities purchase agreement, as reported by Benzinga, confirming the oversubscribed nature of the offering.
The stock opened at $2.30, a 12.2% increase from the prior close of $2.05, and has since surged to $4.20. Trading volume has spiked to 69.0 million shares, which is 88.2 times the 3-month average. The stock has traded as low as $2.25 during the session but has remained above $3.00 for most of the day. Entera Bio has a market cap of $101.0 million, with a trailing twelve-month revenue decline of 100% and an unprofitable position (TTM EPS of -0.26). The stock has traded between $0.91 and $3.22 over the past 52 weeks.
Investors should continue to monitor the progress of the $275 million private placement and its impact on Entera Bio’s clinical development timelines. The company’s ability to advance its Phase 3 programs and manage its capital will be key factors for future performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its oversubscribed $275 million private placement financing. The financing is expected to extend Entera...
ENTERA BIO LTD (ENTX) is drawing unusual attention today. Our newswire has captured 1 story on ENTX across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 24/100). The most recent driver: "Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE" (PR Newswire).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ENTX coverage reads 24/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on ENTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ENTX move explainers: 2026-07-27